Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AB1 | P08238 | 4/20 | 0.49 |
| ▸ | HRH3 | Q9Y5N1 | 11/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.41 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4977984 | 0.91 | HSP90AB1 (0.47) | HSP90AB1HRH3KDM4EKDM2BKCNH2 | |
| SCHEMBL4980394 | 0.88 | KDM2B (0.55) | HSP90AB1HRH3KDM4EKDM2BKCNH2 | |
| SCHEMBL4973602 | 0.88 | HSP90AB1 (0.49) | HSP90AB1HRH3KDM2BKCNH2 | |
| SCHEMBL4977103 | 0.87 | HSP90AB1 (0.63) | HSP90AB1HRH3KDM4EKCNH2L3MBTL3 | |
| SCHEMBL4976292 | 0.87 | HPGD (0.48) | HSP90AB1HRH3KDM4EKDM2BKCNH2 | |
| SCHEMBL4976026 | 0.87 | HRH3 (0.54) | HSP90AB1HRH3KDM4EKDM2BKCNH2 | |
| SCHEMBL4979058 | 0.85 | KDM2B (0.53) | HSP90AB1HRH3KDM2BL3MBTL3L3MBTL1 | |
| SCHEMBL4978554 | 0.85 | HSP90AB1 (0.63) | HSP90AB1HRH3KDM2BKCNH2L3MBTL3 | |
| SCHEMBL4978632 | 0.85 | HSP90AB1 (0.51) | HSP90AB1HRH3KDM4EKDM2BL3MBTL3 | |
| SCHEMBL4981523 | 0.85 | HPGD (0.50) | HSP90AB1HRH3KDM2BL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080051387-A1 | TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES AND RELATED ANALOGUES | NEUROGEN CORPORATION | 2008-02-28 | — | — | US | disclosed |
| US-20080051387-A1 | TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES AND RELATED ANALOGUES | NEUROGEN CORPORATION | 2008-02-28 | — | — | US | disclosed |
| US-20080051387-A1 | TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES AND RELATED ANALOGUES | NEUROGEN CORPORATION | 2008-02-28 | — | — | US | disclosed |
| WO-2007146122-A2 | TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES AND RELATED ANALOGUES | NEUROGEN CORPORATION (US) | 2007-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051387-A1 | TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES AND RELATED ANALOGUES | HRH3, HRH4, HRH2 | HSP90AB1 2652/4885HRH3 1/4885KDM4E 1865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.